Arbutus Biopharma (NASDAQ: ABUS) CFO granted RSUs and 188,400 options

Rhea-AI Filing Summary

Arbutus Biopharma Chief Financial Officer Tuan Nguyen reported new equity awards. On 02/02/2026, he received 73,500 restricted stock units (RSUs), each representing one common share, vesting in three equal annual installments starting one year after the grant, subject to continued service. Common shares will automatically be sold at each vesting date to cover tax withholding in a non‑discretionary way. He was also granted a stock option for 188,400 common shares at an exercise price of $4.39 per share, vesting over four years in substantially equal monthly installments beginning one month after the grant, also conditioned on continued service.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Nguyen Tuan

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	188,400	$0.00	--
Grant/Award	Common Shares	73,500	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 188,400 shares (Direct); Common Shares — 73,500 shares (Direct)

Footnotes (1)

1. Represents the grant of restricted stock units ("RSUs"), which represent a contingent right to receive one common share for each RSU. The RSUs vest in three equal annual installments beginning one year from the grant date, subject to the Reporting Person's continuous service as of each vesting date. Unless otherwise provided, on each vesting date, common shares will automatically be sold to satisfy the Reporting Person's tax withholding obligations in a non-discretionary transaction. Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant. This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date, subject to the Reporting Person's continuous service as of each vesting date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nguyen Tuan

(Last) (First) (Middle)

C/O ARBUTUS BIOPHARMA CORPORATION

701 VETERANS CIRCLE

(Street)

WARMINSTER PA 18974

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Arbutus Biopharma Corp [ ABUS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	02/02/2026		A		73,500(1)	A	$0	73,500	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.39(2)	02/02/2026		A		188,400		(3)	02/02/2036	Common Shares	188,400	$0	188,400	D

Explanation of Responses:

1. Represents the grant of restricted stock units ("RSUs"), which represent a contingent right to receive one common share for each RSU. The RSUs vest in three equal annual installments beginning one year from the grant date, subject to the Reporting Person's continuous service as of each vesting date. Unless otherwise provided, on each vesting date, common shares will automatically be sold to satisfy the Reporting Person's tax withholding obligations in a non-discretionary transaction.

2. Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant.

3. This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the grant date, subject to the Reporting Person's continuous service as of each vesting date.

Remarks:

	/s/ Tuan Nguyen	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Arbutus Biopharma (ABUS) report for its CFO?

Arbutus Biopharma’s CFO Tuan Nguyen reported equity awards, not an open‑market trade. He received 73,500 restricted stock units and a stock option for 188,400 common shares, both granted on February 2, 2026, as part of his compensation package, subject to vesting.

How many RSUs did the Arbutus (ABUS) CFO receive and how do they vest?

The Arbutus CFO received 73,500 RSUs, each equal to one common share. These RSUs vest in three equal annual installments starting one year from the February 2, 2026 grant date, contingent on his continued service at each vesting date with the company.

What are the terms of the Arbutus (ABUS) CFO’s new stock option grant?

The CFO was granted a stock option covering 188,400 common shares at an exercise price of $4.39 per share. The option vests over four years, with 1/48th of the shares vesting in substantially equal monthly installments beginning one month after the grant.

Will Arbutus (ABUS) shares be sold automatically from the CFO’s RSUs?

Yes. When the CFO’s RSUs vest, common shares will automatically be sold to satisfy tax withholding obligations. These sales occur in a non‑discretionary manner on each vesting date, meaning they are triggered by the vesting mechanics rather than separate trading decisions.

Is the Arbutus (ABUS) CFO’s Form 4 transaction a purchase, sale, or grant?

The Form 4 records grants of equity awards, not open‑market purchases or sales. It shows awarded RSUs and a stock option granted at no cost to the CFO, with future vesting schedules and an exercise price of $4.39 for the option shares.